References
- Alison MR. Cancer: Encyclopedia of Life Sciences. London: Nature Publishing Group. 2001
- Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014; 371:424–33. doi: 10.1056/NEJMoa1405095
- Berman HM, Westbrook J, Feng Z et al. The protein data bank. Nucleic Acids Res. 2001; 28: 235–342.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424. doi: 10.3322/caac.21492
- Champion JA, Katare YK, Mitragotri S. Particle shape: a new design parameter for micro- and nanoscale drug delivery carriers. J Control Release. 2007; 121: 3–9
- Champion JA, Mitragotri S. Shape induced inhibition of phagocytosis of polymer particles. Pharm Res. 2009; 26: 244–9
- Chemical Computing Group Inc. Molecular operating environment version 2010. Montreal, Canada. 2010.
- Chen S, Bubeck D, MacDonald BT et al. Structural and functional studies of LRP6 ectodomain reveal a platform for Wnt signaling. Developmental Cell. 2011; 21(5): 848–861.
https://doi.org/10.1016/j.devcel.2011.09.007 - Cheng Z, Biechele T, Wei Z et al. Crystal structures of the extracellular domain of LRP6 and its complex with DKK1. Nature Structural and Molecular Biology. 2011; 18(11): 1204–1210.
https://doi.org/10.1038/nsmb.2139 - Clarke SJ, Rivory LP. Clinical pharmacokinetics of docetaxel. Clin. Pharmacokinet 1999; 36: 99–114.
- Clevers H. Wnt/beta-catenin signaling in development and disease. Cell. 2006; 127 (3): 469–480.
https://doi.org/10.1016/j.cell.2006.10 - Cortesi R, Esposjto E, Luca G, et al. Production of lipospheres as carriers for bioactive compounds. Biomaterials 2002; 23:2283–2294
- Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: An emerging treatment modality for cancer. Nat Rev Drug Discov. 2008; 7(9): 771–782.
- Fujita Y, Kojima K, Hamada N et al. Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun. 2008; 377: 114–9.
- Gradishar WJ, Tjulandin S, Davidson N et al. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005; 23(31): 7794–7803.
- Halgren TA. Merck molecular forcefield. J Comput Chem. 1996; 17(5–6):490–641.
- Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond.). 2016; 11(6); 673–692
- Hotte SJ, Saad F. Current management of castrate-resistant prostate cancer. Curr Oncol. 2010; 17:S72–9. doi: 10.3747/co.v17i0.718
- Huggins C, Hodges CV. Studies on prostatic cancer. I. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941; 1: 293.
- Ibezim A, Olubiyi OO, Ata K, Mbah CJ, Nwodo NJ. Structure-based study of natural poducts with anti-Schistosoma activity. Curr Comput Aided Drug Des. 2017; 13(2): 91–100.
https://doi.org/10.2174/1573409913666170119114859 . - Ibezim A, Nwodo NN, Mbah CM. Computer Aided Drug Design: An Introduction. J Pharmaceutical Development and Industrial Pharmacy. 2019; 1(1): 10–25.
- Jiang W, Kim BYS, Rutka JT, Chan WCW. Nanoparticle-mediated cellular response is size-dependent. Nat Nanotechnol. 2008; 3(3): 145–150.
- Kelly OG, Pinson KI, Skarnes WC. The Wnt co-receptors Lrp5 and Lrp6 are essential for gastrulation in mice. Development. 2004; 131(12): 2803–2815. https://doi.org/10.1242/dev.01137 K
- Li SD, Huang L. Pharmacokinetics and biodistribution of nanoparticles. Molecular Pharmaceutics. 2008; 5 (4): 496–504.
- Litwin MS, Tan HJ. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017; 317:2532–42. doi: 10.1001/jama.2017.7248
- Liu SV, Liu S, Pinski J. Luteinizing hormone-releasing hormone receptor targeted agents for prostate cancer. Expert Opin Investig Drugs. 2011; 20 (6): 769–778. Doi: 10.1517/13543784.2011.574611.
- Liu Y, Tan J, Thomas A, Ou-Yang D, Muzykantov VR. The shape of things to come: importance of design in nanotechnology for drug delivery. Ther Deliv. 2012; 3(2): 181–194.
- Lyubchenko YL, Gall AA, Shlyakhtenko LS. Visualization of DNA and protein-DNA complexes with atomic force microscopy. Methods Mol. Biol. 2014; 1117: 367–384
- MacDonald BT, Tamai K, He X. Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Developmental Cell. 2009; 17(1): 9–26.
https://doi.org/10.1016/j.devcel.2009.06.016 - Malik A, Srinivasan S and Batra J. A New Era of Prostate Cancer Precision Medicine. Front. Oncol. 2019; 9:1263. doi: 10.3389/fonc.2019.01263
- Miao L, Lin CM, Huang L. Stromal barriers and strategies for the delivery of nanomedicine to desmoplastic tumors. J. Controlled Release. 2015; 219: 192–204.
- Muj C, Mukhopadhyay S, Jana P, Kondapi AK. Synergistic action of lactoferrin in enhancing the safety and effectiveness of docetaxel treatment against prostate cancer. Cancer Chemother Pharmacol. 2023; 91(5): 375–387.
- Paliwal R, Paliwal SR, Agrawal GP, et al. Biomimetic solid lipid nanoparticles for oral bioavailability enhancement of low molecular weight heparin and its lipid conjugates: in vitro and in vivo evaluation. Mol Pharm. 2011; 8(4): 1314–1321.
- Paul D, Achouri S, Yoon YZ, et al. Phagocytosis dynamics depends on target shape. Biophys J. 2013; 105 (5):1143–50
- Ramaswamy B, Puhalla S. Docetaxel: a tubulin-stabilizing agent approved for the management of several solid tumors. Drugs Today (Barc). 2006; 42 (4): 265–279. doi: 10.1358/dot.2006.42.4.968648.
- Rismani E, Rahimi H, Arab SS, Azadmanesh K, Karimipoor M, Teimoori-Toolabi L. Computationally design of inhibitory peptides against Wnt signaling pathway: In silico insight on complex of DKK1 and LRP6. International Journal of Peptide Research and Therapeutics. 2018; 24(1): 49–60.
https://doi.org/10.1007/s10989-017-9589-1 . - Rowinsky EK. The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Annu. Rev. Med. 1997; 48: 353–374.
- Sanna V, Roggio AM, Posadino AM. et al. Novel docetaxel-loaded nanoparticles based on poly(lactide-co-caprolactone) and poly(lactide-co-glycolide-co-caprolactone) for prostate cancer treatment: formulation, characterization, and cytotoxicity studies. Nanoscale Res Lett. 2011; 6: 260.
https://doi.org/10.1186/1556-276X-6-260 - Setyawati MI, Tay CY, Bay BH, Leong DT. Gold Nanoparticles Induced Endothelial Leakiness Depends on Particle Size and Endothelial Cell Origin. ACS Nano. 2017; 11 (5): 5020–5030
- Shimoni O, Yan Y, Wang YJ, Caruso F. Shape-dependent cellular processing of polyelectrolyte capsules. ACS Nano. 2013; 7(1):522–30
- Shlyakhtenko LS, Gall AA, Filonov A, Cerovac Z, Lushnikov A, Lyubchenko YL. Silatrane-based surface chemistry for immobilization of DNA, protein-DNA complexes and other biological materials. Ultramicroscopy. 2003; 97: 1–4: 279–287
- Singh S, Chitkara D, Mehrazin R, Behrman SW, Wake RW, Mahato RI. Chemoresistance in prostate cancer cells is regulated by miRNAs and hedgehog pathway. PLoS One 2012; 7:e40021.
- Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med. 2018; 378: 1408–18. doi: 10.1056/NEJMoa1715546
- Tahir SA, Yang G, Goltsov A, Song KD, Ren C, Wang J, et al. Caveolin-1-LRP6 signaling module stimulates aerobic glycolysis in prostate cancer. Cancer Res. 2013; 73: 1900–1911. doi: 10.1158/0008-5472.can-12-3040
- Tanida S, Kurokawa T, Sato H, Kadota K, Tozuka Y. Evaluation of the Micellization Mechanism of an Amphipathic Graft Copolymer with Enhanced Solubility of Ipriflavone. Chemical and Pharmaceutical Bulletin. 2016; 64 (1): 68–72.
https://doi.org/10.1248/cpb.c15-00655 - Uster PS, Working PK, Vaage J. Pegylated liposomal doxorubicin (DOXIL®, CAELYX®) distribution in tumour models observed with confocal laser scanning microscopy. Int J Pharm. 1998; 162(1–2):77–86.
- Venkataraman S, Hedrick JL, Ong ZY, et al. The effects of polymeric nanostructure shape on drug delivery. Adv Drug Deliv Rev. 2011; 63:1228–46
- Wang G, Liu G, Ye Y, Fu Y, Zhang X. Upregulation of miR-34a by diallyldisulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/akt signaling pathway. Oncol Lett. 2016; 11:2661–7.
- Wang ZM, Luo JQ, Xu LY, Zhou HH, Zhang W. Harnessing low-density lipoprotein receptor protein 6 (LRP6) genetic variation and Wnt signaling for innovative diagnostics in complex diseases. The Pharmacogenomics Journal. 2018; 18: 351–358
- Wen D, Peng Y, Lin F, Singh RK, Mahato RI. Micellar Delivery of miR-34a Modulator Rubone and Paclitaxel in Resistant Prostate Cancer Cancer Res. 2017; 77(12): 3244–3254. doi: 10.1158/0008-5472.CAN-16-2355
- Williams BO, Insogna KL. Where Wnts went: The exploding field of Lrp5 and Lrp6 signaling in bone. Journal of Bone and Mineral Research 2009; 24(2): 171–178.
https://doi.org/10.1359/jbmr.081235 - Xiao Z, Li CH, Chan SL, Xu F, Feng L, Wang Y, et al. A small-molecule modulator of the tumor-suppressor miR34a inhibits the growth of hepatocellular carcinoma. Cancer Res 2014; 74: 6236–47.
- Zhang K, Fang H, Chen Z, et al. Shape effects of nanoparticles conjugated with cell-penetrating peptides (HIV Tat PTD) on CHO cell uptake. Bioconjug Chem 2008; 19:1880–7
- Zhang Y, Tekobo S, Tu Y, et al. Permission to enter cell by shape: nanodisk vs nanosphere. ACS Appl Mater Interfaces 2012; 4(8): 4099–4105